Nine traditional Chinese herbal formulas for the treatment of depression: An ethnopharmacology, phytochemistry, and pharmacology review

Neuropsychiatric Disease and Treatment

Volumn 12, Issue , 2016, Pages 2387-2402

  Feng, Dan Dan ^a   Tang, Tao ^a   Lin, Xiang Ping ^a   Yang, Zhao Yu ^a   Yang, Shu ^a   Xia, Zi An ^a   Wang, Yun ^a   Zheng, Piao ^a   Wang, Yang ^a   Zhang, Chun Hu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antidepressant; Chinese herbal formula; Pharmacological bioactivity; Phytochemistry; Traditional Chinese medicine

Indexed keywords

BANXIA HOUPO; CHAIHU SHUGANSAN; CITALOPRAM; CITRAL; FLUOXETINE; FLUPENTIXOL; GANMAIDAZAO; GUANOSINE; HERBACEOUS AGENT; HONOKIOL; KAIXINSAN; LINALOOL; MAGNOLOL; MELITRACEN; NEROLIDOL; PAROXETINE; ROSMARINIC ACID; SERTRALINE; SHUGANJIEYU; SINISAN; UNCLASSIFIED DRUG; WULING; XIAOYAOSAN; YUEJU; ZINGERONE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AMINO ACID METABOLISM; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; BIOLOGICAL ACTIVITY; BRAIN BLOOD FLOW; CHEMICAL COMPOSITION; CHINESE MEDICINE; CHRONIC FATIGUE SYNDROME; CLINICAL PRACTICE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ENERGY METABOLISM; ETHNOPHARMACOLOGY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROESOPHAGEAL REFLUX; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; HYPERSALIVATION; INSOMNIA; LIPID PEROXIDATION; MELANCHOLIA; NAUSEA; NEURASTHENIA; NONHUMAN; NOSE OBSTRUCTION; PHYTOCHEMISTRY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RASH; REVIEW; SINGLE DRUG DOSE; STOMACH DISEASE; SYSTEMATIC REVIEW; TENESMUS; THORAX PAIN; TRANQUILIZING ACTIVITY; VOMITING; XEROSTOMIA; YIN DEFICIENCY;

EID: 84988982856     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S114560     Document Type: Review

References (141)

1. Patten SB, Williams JV, Lavorato DH, Wang JL, McDonald K, Bulloch AG. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015;60(1):23–30.
2. Al-Hamzawi AO, Bruffaerts R, Bromet EJ, AlKhafaji AM, Kessler RC. The epidemiology of major depressive episode in the Iraqi general population. PLoS One. 2015;10(7):e0131937.
3. Hankin BL. Depression from childhood through adolescence: risk mechanisms across multiple systems and levels of analysis. Curr Opin Psychol. 2015;4:13–20.
4. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471–481.
5. Global Burden of Disease Study 2013 collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.
6. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–341.
7. Greenberg PE, Fournier A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):115–155.
8. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–138.
9. Zhong BL, Liu TB, Chan SS, et al. Prevalence and correlates of major depressive disorder among rural-to-urban migrant workers in Shenzhen, China. J Affect Disord. 2015;183:1–9.
10. Li D, Zhang DJ, Shao JJ, Qi XD, Tian L. A meta-analysis of the prevalence of depressive symptoms in Chinese older adults. Arch Gerontol Geriatr. 2014;58(1):1–9.
11. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41–47.
12. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
13. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143–150.
14. Monteggia LM, Malenka RC, Deisseroth K. Depression: the best way forward. Nature. 2014;515(7526):200–201.
15. Plesničar BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence. 2014;8:603–612.
16. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011; 378(9791): 621–631.
17. Liu J, Fang Y, Yang L, Qin X, Du G, Gao X. A qualitative, and quantitative determination and pharmacokinetic study of four polyacetylenes from radix bupleuri by UPLC-PDA-MS. J Pharm Biomed Anal. 2015; 111:257–265.
18. Wu R, Zhu D, Xia Y, et al. A role of yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study. Neuropsychiatr Dis Treat. 2015;11:2013–2021.
19. Qu M, Tang QS. [Investigation on the relationship between depression and TCM depression syndrome]. Beijing Zhong Yi Yao Da Xue Xue Bao. 2004;27(1):11–13. Chinese.
20. Chang HS, Duan XH, Liang JC, Wang QG. [Origin of TCM doctrine of depression syndrome]. Beijing Zhong Yi Yao Da Xue Xue Bao. 2011; 34(10):653–658, 661. Chinese.
21. Qu F, Cai X, Gu Y, et al. Chinese medicinal herbs in relieving perimenopausal depression: a randomized, controlled trial. J Altern Complement Med. 2009;15(1):93–100.
22. Luo L, Wang JN, Kong LD, Jiang QG, Tan RX. Antidepressant effects of banxia houpu decoction, a traditional Chinese medicinal empirical formula. J Ethnopharmacol. 2000;73(1 2):277–281.
23. Chen HY, Cho WC, Sze SC, Tong Y. Treatment of menopausal symptoms with Er-xian decoction: a systematic review. Am J Chin Med. 2008; 36(2):233–244.
24. Wang Y, Fan R, Huang X. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula chaihu-shugan-san in depression. J Ethnopharmacol. 2012;141(2):571–577.
25. Yeung WF, Chung KF, Ng KY, et al. Prescription of Chinese herbal medicine in pattern-based traditional Chinese medicine treatment for depression: a systematic review. Evid Based Complement Alternat Med. 2015;2015:160189.
26. Zhao YQ, Teng J, Yang HJ. [Analysis on medication regularity of modern traditional Chinese medicines in treating melancholia based on data mining technology]. Zhongguo Zhong Yao Za Zhi. 2015;40(10): 2042–2046. Chinese.
27. Yeung WF, Chung KF, Ng KY, Yu YM, Ziea ET, Ng BF. A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression. J Psychiatr Res. 2014;57:165–175.
28. Wang DL. [Target component analysis of banxia houpo decoction]. Chin Tradit Pat Med. 1991;13(10):47. Chinese.
29. Xu Q, Ou Yang Z, Chang Y, Fu DS, Kong LD. [Principal, assistant, compleaent [sic], guide compatibility of banxiahoupo decoction on contents of honokioi and magnolol]. Zhongguo Shi Yan Fang Ji Xue Za Zhi. 2008;14(10):1–3. Chinese.
30. Xu Q, Wu LL, Wang CP, Wang SJ, Kong LD. [Effects of different compatibility of banxiahoupu decoction on changes of volatile oils by GC-MS]. Zhongguo Shi Yan Fang Ji Xue Za Zhi. 2009;15(2): 5–10. Chinese.
31. Guo Y, Kong L, Wang Y, Huang Z. Antidepressant evaluation of polysaccharides from a Chinese herbal medicine banxia-houpu decoction. Phytother Res. 2004;18(3):204–207.
32. Bo P, Chen QM, Zhu HH, et al. Clinical observations on 46 cases of globus hystericus treated with modified banxia houpu decoction. J Tradit Chin Med. 2010;30(2):103–107.
33. Yi LT, Zhang L, Ding AW, Xu Q, Zhu Q, Kong LD. Orthogonal array design for antidepressant compatibility of polysaccharides from banxia-houpu decoction, a traditional Chinese herb prescription in the mouse models of depression. Arch Pharm Res. 2009;32(10): 1417–1423.
34. Wang Y, Kong L, Chen Y. Behavioral and biochemical effects of fractions prepared from banxia houpu decoction in depression models in mice. Phytother Res. 2005;19(6):526–529.
35. Zhang W, Li J, Zhu J, Shi Z, Wang Y, Kong L. Chinese medicine banxia-houpu decoction regulates c-Fos expression in the brain regions in chronic mild stress model in rats. Phytother Res. 2004;18(3):200–203.
36. Li JM, Kong LD, Wang YM, Cheng CH, Zhang WY, Tan WZ. Behavioral and biochemical studies on chronic mild stress models in rats treated with a Chinese traditional prescription banxia-houpu decoction. Life Sci. 2003;74(1):55–73.
37. Ma Z, Ji W, Qu R, et al. Metabonomic study on the antidepressant-like effects of banxia houpu decoction and its action mechanism. Evid Based Complement Alternat Med. 2013;2013:213739.
38. Su ZH, Zou GA, Preiss A, Zhang HW, Zou ZM. Online identification of the antioxidant constituents of traditional Chinese medicine formula chaihu-shu-gan-san by LC-LTQ-Orbitrap mass spectrometry and microplate spectrophotometer. J Pharm Biomed Anal. 2010;53(3): 454–461.
39. Qiu XJ, Huang X, Chena ZQ, Ren P. Simultaneous determination of 16 chemical constituents in the traditional Chinese medicinal prescription si-ni-san and chaihu-shugan-san by ultra performance liquid chromatography coupled with photodiode array detection. Asian J Chem. 2011; 23(12):5301–5307.
40. Li SQ, Su ZH, Peng JB, Zou ZM, Yu CY. In vitro and in vivo antioxidant effects and the possible relationship between the antidepression efficacy of traditional Chinese medicine formulation chaihu shugan san. Chin J Nat Med. 2010;8(5):353–361.
41. Qiu J, Hu SY, Shi GQ, Wang SE. Changes in regional cerebral blood flow with chaihu-shugan-san in the treatment of major depression. Pharmacogn Mag. 2014;10(40):503–508.
42. Wang S, Hu S, Zhang C, Qiu J, Li Y. Antidepressant-like activity of chaihu-shugan-san aqueous extract in rats and its possible mechanism. Pharmacogn Mag. 2014;10 Suppl 1:S50–S56.
43. Chen S, Asakawa T, Ding S, et al. Chaihu-shugan-san administration ameliorates perimenopausal anxiety and depression in rats. PLoS One. 2013; 8(8):e72428.
44. Li YH, Zhang CH, Qiu J, et al. Antidepressant-like effects of chaihu-shugan-san via SAPK/JNK signal transduction in rat models of depression. Pharmacogn Mag. 2014;10(39):271–277.
45. Yang P, Li L, Liu XJ, et al. Effect of chaihu-shugan-san on the mRNA expression of the 5-HT1A receptor and cellular proliferation in the hippocampus of epileptic rats with depression. Exp Ther Med. 2016; 11(1):124–130.
46. Su ZH, Li SQ, Zou GA, et al. Urinary metabonomics study of anti-depressive effect of chaihu-shu-gan-san on an experimental model of depression induced by chronic variable stress in rats. J Pharm Biomed Anal. 2011;55(3):533–539.
47. Qiu J, Hu SY, Zhang CH, et al. The effect of chaihu-shugan-san and its components on the expression of ERK5 in the hippocampus of depressed rats. J Ethnopharmacol. 2014;152(2):320–326.
48. Yeung WF, Chung KF, Ng KY, Shi GQ, Wang SE, Xiang T. A meta-analysis of the efficacy and safety of traditional Chinese medicine formula ganmai dazao decoction for depression. J Ethnopharmacol. 2014; 153(2):309–317.
49. Ma XJ, Zhao J, Feng ZY, et al. [Effects of modified ganmai dazao decoction on neuroendocrine system in patients with climacteric depression]. Zhongguo Zhong Yao Za Zhi. 2014;39(23):4680–4684. Chinese.
50. Lou JS, Li CY, Yang XC, Fang J, Yang YX, Guo JY. Protective effect of gan mai da zao decoction in unpredictable chronic mild stress-induced behavioral and biochemical alterations. Pharm Biol. 2010;48(12): 1328–1336.
51. El-Alfy AT, Abourashed EA, Matsumoto RR. Nature against depression. Curr Med Chem. 2012;19(14):2229–2241.
52. Zhou XY, Qin XD, Geng LF. [Ganmai dazao decoction in clinical observation on treatment of 30 cases of post stroke depression]. J Sichuan Tradit Chin Med. 2009;27(10):75–76. Chinese.
53. Zhu KY, Fu Q, Xie HQ, et al. Quality assessment of a formulated Chinese herbal decoction, kaixinsan, by using rapid resolution liquid chromatography coupled with mass spectrometry: a chemical evaluation of different historical formulae. J Sep Sci. 2010;33(23 24):3666–3674.
54. Zhang X, Li Q, Lv C, et al. Characterization of multiple constituents in kai-xin-san prescription and rat plasma after oral administration by liquid chromatography with quadrupole time-of-flight tandem mass spectrometry. J Sep Sci. 2015;38(12):2068–2075.
55. Liu JY, Xiao SY, Shang WF, Xu LZ, Yang SL. A new minor triterpene saponin from kaixin-san prescription. J Asian Nat Prod Res. 2005;7(4): 643–648.
56. Zhu KY, Xu SL, Choi RC, et al. Kai-xin-san, a Chinese herbal decoction containing ginseng radix et rhizoma, polygalae radix, acori tatarinowii rhizoma, and poria, stimulates the expression and secretion of neurotrophic factors in cultured astrocytes. Evid Based Complement Alternat Med. 2013;2013:731385.
57. Hu Y, Zhou XJ, Liu P, et al. Antidepressant and neuroprotective effect of the Chinese herb kaixinsan against lentiviral shRNA knockdown brain-derived neurotrophic factor-induced injury in vitro and in vivo. Neuropsychobiology. 2014;69(3):129–139.
58. Yan L, Xu SL, Zhu KY, et al. Optimizing the compatibility of paired-herb in an ancient Chinese herbal decoction kai-xin-san in activating neurofilament expression in cultured PC12 cells. J Ethnopharmacol. 2015;162:155–162.
59. Bao ZX, Zhao GP, Sun W, Chen BJ. [Clinical curative effects of kaixin powder on depression with mild or moderate degree]. Chin Arch Tradit Chin Med. 2011;28(5):987–988. Chinese.
60. Dang H, Sun L, Liu X, et al. Preventive action of kai xin san aqueous extract on depressive-like symptoms and cognition deficit induced by chronic mild stress. Exp Biol Med (Maywood). 2009;234(7): 785–793.
61. Zhu KY, Mao QQ, Ip SP, et al. A standardized Chinese herbal decoction, kai-xin-san, restores decreased levels of neurotransmitters and neurotrophic factors in the brain of chronic stress-induced depressive rats. Evid Based Complement Alternat Med. 2012;2012:149256.
62. Dong XZ, Li ZL, Zheng XL, Mu LH, Zhang GQ, Liu P. A representative prescription for emotional disease, ding-zhi-xiao-wan restores 5-HT system deficit through interfering the synthesis and transshipment in chronic mild stress-induced depressive rats. J Ethnopharmacol. 2013;150(3):1053–1061.
63. Cai C, Qian GQ, Zhao GP, Peng X, Liang XB. [Study on regulatory effect of kaixin san on endogenous melatonin biosynthesis in rat depression model]. Zhongguo Zhong Yao Za Zhi. 2012;37(11): 1638–1641. Chinese.
64. Huang YL, Liang XB, Qian LQ, et al. Effects of kaixin powder on melatonin receptor expression and 125I-Mel binding affinity in a rat model of depression. Chin J Integr Med. 2015;21(7):507–515.
65. Mu LH, Huang ZX, Liu P, Hu Y, Gao Y. Acute and subchronic oral toxicity assessment of the herbal formula kai-xin-san. J Ethnopharmacol. 2011;138(2):351–357.
66. Qiao HY, Luo R, Wu J, et al. [UPLC-MS fingerprint of shugan jieyu capsules]. Zhong Cao Yao. 2014;45(2):208–213. Chinese.
67. Huang L, Chen LJ, Liu LL, et al. [A systematic review of therapeutic efficacy and safety of shugan jieyu capsules in the treatment of mild to moderate depression]. China Pharm. 2013;24(32):3043–3046. Chinese.
68. Zhang X, Kang D, Zhang L, Peng L. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging Ment Health. 2014;18(8):941–953.
69. Xie M, Jiang W, Yang H. Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial. Shanghai Arch Psychiatry. 2015;27(2):103–110.
70. Fu JH, Liu Y, Wang QY, Zhao JP. [Effect of shuganjieyu capsules on neuronal apoptosis in hippocampal CA3 area and the expression of caspase-3 in the brain of rat depression model]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37(12):1198–1204. Chinese.
71. Fu J, Zhang Y, Wu R, et al. Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression. Neural Regen Res. 2014;9(5):489–497.
72. Yao J, Li QW, Ji JL, et al. [Efficacy and safety of different doses of shuganjieyu capsules in treating mild or moderate depressive disorder: a multicenter, random, open and controlled trial]. Zhongguo Xin Yao Yu Lin Chuan Za Zhi. 2014;33(8):568–572. Chinese.
73. Guo R, Shu Y, Zhang L, Cao Y, Ding A, Yao W. [Analysis of chemical composition of sini san by ultra-performance liquid chromatography-electrospray ionization-mass spectrometry]. Zhongguo Zhong Yao Za Zhi. 2011;36(22):3114–3118. Chinese.
74. Qiao Y, Wen J, Song Y, Lu X, Xiong Z, Li F. [Study on in vitro and in vivo material base of Sini San by UPLC-PDA-MS/MS]. Zhongguo Zhong Yao Za Zhi. 2012;37(11):1672–1676. Chinese.
75. Yan Z, Chen Y, Li T, Zhang J, Yang X. Identification of metabolites of si-ni-san, a traditional Chinese medicine formula, in rat plasma and urine using liquid chromatography/diode array detection/triple-quadrupole spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;885 886:73–82.
76. Wang YT, Tan QR, Sun LL, et al. Possible therapeutic effect of a traditional Chinese medicine, sinisan, on chronic restraint stress related disorders. Neurosci Lett. 2009;449(3):215–219.
77. Li Y, Sun Y, Ma X, et al. Effects of sini san used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression. J Tradit Chin Med. 2013;33(5):674–681.
78. Qin L. [Study on the antidepressant mechanism of sini san]. Dang Dai Yi Xue. 2010;16(14):29–30. Chinese.
79. Yi LT, Li J, Liu BB, Li CF. Screening of the antidepressant-like effect of the traditional Chinese medicinal formula si-ni-san and their possible mechanism of action in mice. Pharmacognosy Res. 2013;5(1): 36–42.
80. Wang HH, Zhang BX, Ye XT, He SB, Zhang YL, Wang Y. [Study on mechanism for anti-depression efficacy of sini san through auxiliary mechanism elucidation system for Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2015;40(19):3723–3728. Chinese.
81. Lu JX, Zhu M, Chen Y, Zhang P, Fang L. [HPLC specific chromatogram of chemical constituents of wuling capsules]. Yao Wu Fen Xi Za Zhi. 2011;4:764–767. Chinese.
82. Chen Y, Lu J, Zhu M, Luo L. [Determination of multiple constituents in wuling capsules by HPLC simultaneously]. Zhongguo Zhong Yao Za Zhi. 2012;37(2):218–221. Chinese.
83. Lu JX, Lei L, Chen Y, Chen J, Zhu M. [Chemical constituents of wuling fermentative powder]. Zhongguo Xian Dai Ying Yong Yao Xue. 2014;31(5):541–543. Chinese.
84. He XR, Liu P. [Determination of 14 kinds of amino acids in wuling capsule by HPLC-FLD]. Chin Tradit Pat Med. 2010;32(8): 1358–1361. Chinese.
85. Peng L, Zhang X, Kang DY, Liu XT, Hong Q. Effectiveness and safety of wuling capsule for post stroke depression: a systematic review. Complement Ther Med. 2014;22(3):549–566.
86. Wang XJ, Li J, Zou QD, Jin L. [Wuling capsule for climacteric patients with depression and anxiety state: a randomized, positive parallel controlled trial]. Zhong Xi Yi Jie He Xue Bao. 2009;7(11): 1042–1046. Chinese.
87. Peng WF, Wang X, Hong Z, et al. The anti-depression effect of Xylaria nigripes in patients with epilepsy: a multicenter randomized double-blind study. Seizure. 2015;29:26–33.
88. Li DQ, Li XJ, Duan JF, Cai W. Wuling capsule promotes hippocampal neurogenesis by improving expression of connexin 43 in rats exposed to chronic unpredictable mild stress. Zhong Xi Yi Jie He Xue Bao. 2010; 8(7):662–669.
89. Li DQ, Li XJ, Duan JF, Cai W. Effects of wuling capsule on hippocampal dependent cognitive changes in post-stroke depression rats. Int J Pharmacol. 2011;7(1):50–57.
90. Li D, Zheng J, Wang M, et al. Wuling powder prevents the depression-like behavior in learned helplessness mice model through improving the TSPO mediated-mitophagy. J Ethnopharmacol. 2016;186:181–188.
91. Tan YF, Liao ZL, Qiu YJ, Zhu JP, Yu EY. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like effect of wuling mycelia powder in rat. Biomed Pharmacother. 2016;78:60–65.
92. Pharmacopoeia Commission of the People’s Republic of China. Pharmacopoeia of the People’s Republic of China. Beijing: China Medical Science Press; 2015.
93. Liao ML, Yu J. [Wuling capsule]. Zhongguo Xin Yao Za Zhi. 2000; 9(11):797. Chinese.
94. Han J, Gao SQ. [The clinical applications and adverse effects of wuling capsule]. China Pharm. 2007;18(15):1184–1186. Chinese.
95. Gao XX, Cui J, Zheng XY, et al. An investigation of the antidepressant action of xiaoyaosan in rats using ultra performance liquid chromatography-mass spectrometry combined with metabonomics. Phytother Res. 2013;27(7):1074–1085.
96. Zhou Y, Ren Y, Ma Z, et al. Identification and quantification of the major volatile constituents in antidepressant active fraction of xiaoyaosan by gas chromatography-mass spectrometry. J Ethnopharmacol. 2012; 141(1):187–192.
97. Zhu X, Xia O, Han W, et al. Xiao yao san improves depressive-like behavior in rats through modulation of β-arrestin 2-mediated pathways in hippocampus. Evid Based Complement Alternat Med. 2014; 2014:902516.
98. Yin SH, Wang CC, Cheng TJ, et al. Room-temperature super-extraction system (RTSES) optimizes the anxiolytic-and antidepressant-like behavioral effects of traditional xiao-yao-san in mice. Chin Med. 2012;7(1):24.
99. Zhang Y, Han M, Liu Z, Wang J, He Q, Liu J. Chinese herbal formula xiao yao san for treatment of depression: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2012; 2012:931636.
100. Zhou Y, Lu L, Li Z, et al. Antidepressant-like effects of the fractions of xiaoyaosan on rat model of chronic unpredictable mild stress. J Ethnopharmacol. 2011;137(1):236–244.
101. Liang Y, Guo XL, Chen JX, Yue GX. Effects of the Chinese traditional prescription xiaoyaosan decoction on chronic immobilization stress-induced changes in behavior and ultrastructure in rat hippocampus. Evid Based Complement Alternat Med. 2013;2013:984797.
102. Ding XF, Zhao XH, Tao Y, et al. Xiao yao san improves depressive-like behaviors in rats with chronic immobilization stress through modulation of locus coeruleus-norepinephrine system. Evid Based Complement Alternat Med. 2014;2014:605914.
103. Li P, Tang XD, Cai ZX, et al. CNP signal pathway up-regulated in rectum of depressed rats and the interventional effect of xiaoyaosan. World J Gastroenterol. 2015;21(5):1518–1530.
104. Tian JS, Peng GJ, Gao XX, et al. Dynamic analysis of the endogenous metabolites in depressed patients treated with TCM formula xiaoyaosan using urinary 1H NMR-based metabolomics. J Ethnopharmacol. 2014; 158 Pt A:1–10.
105. Liu CC, Wu YF, Feng GM, et al. Plasma-metabolite-biomarkers for the therapeutic response in depressed patients by the traditional Chinese medicine formula xiaoyaosan: a 1H NMR-based metabolomics approach. J Affect Disord. 2015;185:156–163.
106. Tian JS, Peng GJ, Wu YF, et al. A GC-MS urinary quantitative metabolomics analysis in depressed patients treated with TCM formula of xiaoyaosan. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1026:227–235.
107. Wang YH, Li B, Cai GX, Yang H. [Comparative study on effect of three preparations of xiaoyao formula on soothing liver and strengthening spleen]. Zhongguo Zhong Yao Za Zhi. 2012;37(19): 2951–2955. Chinese.
108. Zhu ZF, Zhang SY, Zhou GZ. [Identification of Gardenia jasminoides Ellis and its six Chinese patent medicine by TLC]. Chin Tradit Pat Med. 1985(12):31–32. Chinese.
109. Di WF, Wei XH, Zhang SX, Wang ZT. [HPLC determination of ligustilide, α-cyperone and atrctylodin in YJ-XCC1Z3 extract of yueju pills]. Yao Wu Fen Xi Za Zhi. 2009;29(5):693–696. Chinese.
110. Wei XH, Chen Y, Xia GX, Shen JS. [Antidepressant effect of “yueju pills” ethanol extract and water extract in mice models of depression]. Shang Hai Zhong Yi Yao Za Zhi. 2006;40(8):69–70. Chinese.
111. Wei XH, Cheng XM, Shen JS, Wang ZT. Antidepressant effect of yueju-wan ethanol extract and its fractions in mice models of despair. J Ethnopharmacol. 2008;117(2):339–344.
112. Wei XH, Chang HS, Zhai WF, Wang ZT. [Experimental studies on treatment of depression with YJ-XCC1Z3 in mouse models]. Zhongguo Zhong Yao Za Zhi. 2007;32(24):2628–2631. Chinese.
113. Xue W, Zhou X, Yi N, et al. Yueju pill rapidly induces antidepressant-like effects and acutely enhances BDNF expression in mouse brain. Evid Based Complement Alternat Med. 2013;2013:184367.
114. Tang J, Xue W, Xia B, et al. Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of yueju and ketamine on chronically stressed mice. Sci Rep. 2015;5: 13573.
115. Xia B, Zhang H, Xue W, et al. Instant and lasting down-regulation of NR1 expression in the hippocampus is associated temporally with antidepressant activity after acute yueju. Cell Mol Neurobiol. 2016; 36(7):1189–1196.
116. Xue W, Wang W, Gong T, et al. PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of yueju but not ketamine. Sci Rep. 2016;6:26331.
117. Willner P, Scheel-Krüger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev. 2013;37(10 Pt 1): 2331–2371.
118. Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171(4):453–462.
119. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704.
120. Hasselmann HW. Ketamine as antidepressant? Current state and future perspectives. Curr Neuropharmacol. 2014;12(1):57–70.
121. Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs. 2012;72(10):1313–1333.
122. Chan WM, Liang Y, Wai MS, Hung AS, Yew DT. Cardiotoxicity induced in mice by long term ketamine and ketamine plus alcohol treatment. Toxicol Lett. 2011;207(2):191–196.
123. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010; 105(1):121–133.
124. Yeung WF, Chung KF, Poon MM, et al. Chinese herbal medicine for insomnia: a systematic review of randomized controlled trials. Sleep Med Rev. 2012;16(6):497–507.
125. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008;105(12): 4826–4831.
126. Qiu J. ‘Back to the future’ for Chinese herbal medicines. Nat Rev Drug Discov. 2007; 6(7):506–507.
127. Wu L, Wang Y, Li Z, Zhang B, Cheng Y, Fan X. Identifying roles of “jun-chen-zuo-shi” component herbs of qishenyiqi formula in treating acute myocardial ischemia by network pharmacology. Chin Med. 2014;9:24.
128. Ung CY, Li H, Cao ZW, Li YX, Chen YZ. Are herb-pairs of traditional Chinese medicine distinguishable from others? Pattern analysis and artificial intelligence classification study of traditionally defined herbal properties. J Ethnopharmacol. 2007;111(2):371–377.
129. Dong X, Fan Y. [Internal relations between seven methods in prescription compatibility and toxicity and therapeutic effects of complex prescription]. Zhong Hua Zhong Yi Yao Xue Kan. 2008;26(3): 618–619. Chinese.
130. Chang X, Jia H, Zhou C, et al. Role of bai-shao towards the antidepressant effect of chaihu-shu-gan-san using metabonomics integrated with chemical fingerprinting. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1006:16–29.
131. Lv H, Sun H, Sun W, et al. Pharmacokinetic studies of a Chinese triple herbal drug formula. Phytomedicine. 2008;15(11):993–1001.
132. Zheng Q, Yue PF, Wu B, Hu PY, Wu ZF, Yang M. Pharmacokinetics comparative study of a novel Chinese traditional herbal formula and its compatibility. J Ethnopharmacol. 2011;137(1):221–225.
133. Zheng M, Zhou H, Wan H, Chen YL, He Y. Effects of herbal drugs in mahuang decoction and their main components on intestinal transport characteristics of Ephedra alkaloids evaluated by a Caco-2 cell monolayer model. J Ethnopharmacol. 2015;164:22–29.
134. Pharmacopoeia Commission of the People’s Republic of China. Pharmacopoeia of the People’s Republic of China. Beijing: Chemical Industry Press; 2005.
135. Lin HJ, Kao ST, Siao YM, Yeh CC. The Chinese medicine sini-san inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells. BMC Complement Altern Med. 2015;15:348.
136. Li X, Wu L, Liu W, et al. A network pharmacology study of Chinese medicine qishenyiqi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action. PLoS One. 2014;9(5):e95004.
137. Sun C, Geng C, Yin X, Huang X, Chen J. Natural products as antidepressants documented in Chinese patents from 1992 to 2013. J Asian Nat Prod Res. 2015;17(2):188–198.
138. Liu LY, Feng B, Chen J, et al. Herbal medicine for hospitalized patients with severe depressive episode: a retrospective controlled study. J Affect Disord. 2015;170:71–77.
139. Saki K, Bahmani M, Rafieian-Kopaei M. The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression): a review. Asian Pac J Trop Med. 2014;7 Suppl 1: S34–S42.
140. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013; 11(2):110–120.
141. Jun JH, Choi TY, Lee JA, Yun KJ, Lee MS. Herbal medicine (gan mai da zao decoction) for depression: a systematic review and meta-analysis of randomized controlled trials. Maturitas. 2014;79(4):370–380.